MicroPort NeuroTech (02172.HK) Surges Over 5% as MicroPort Medical Terminates Merger and Brain-Computer Interface Commercialization Accelerates

Zhitong Finance APP learned that MicroPort NeuroTech (02172) rose more than 5% in early trading. As of press time, it was up 3.03%, trading at HK$11.21, with a turnover of HK$1.5032 million.

In terms of news, MicroPort Medical announced the termination of the consolidation of MicroPort NeuroTech. The reason is that after appointing an independent non-executive director, MicroPort NeuroTech determined, based on accounting policies, that it could no longer control MicroPort NeuroTech but still retained significant influence. The termination of consolidation is expected to result in the recognition of a gain from the deemed disposal of a subsidiary.

Furthermore, Elon Musk recently stated that his brain-computer interface (BCI) company, Neuralink, will initiate mass production of BCI devices in 2026, while simultaneously advancing the full automation of surgical procedures. Guotai Haitong Securities pointed out that driven by multiple factors—including breakthroughs in technological innovation, policy support and guidance, and capital investment—the BCI industry is poised for significant development opportunities. Demand is expected to surge in downstream markets such as healthcare and consumer goods, indicating promising market prospects.